Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.30 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15703475 | 0.90 | MAPT (0.33) | MAPTCACNA1BAPBA1SMN1; SMN2CYP3A4 | |
| SCHEMBL3634048 | 0.85 | MAPT (0.39) | MAPTCACNA1BAPBA1SMN1; SMN2CYP3A4 | |
| SCHEMBL3637092 | 0.85 | MAPT (0.39) | MAPTCACNA1BAPBA1SMN1; SMN2CYP3A4 | |
| SCHEMBL11861945 | 0.84 | SMN1; SMN2 (0.36) | SMN1; SMN2ALOX5TSHRALDH1A1 | |
| SCHEMBL3146412 | 0.83 | SMN1; SMN2 (0.46) | MAPTCACNA1BAPBA1SMN1; SMN2CYP3A4 | |
| SCHEMBL4412611 | 0.82 | ALOX5 (0.34) | SMN1; SMN2ALOX5ARG1ARG2GRIK1 | |
| SCHEMBL929643 | 0.82 | KIF11 (0.37) | SMN1; SMN2ALOX5ALDH1A1ARG1ARG2 | |
| SCHEMBL14160472 | 0.82 | KIF11 (0.37) | SMN1; SMN2ALOX5ALDH1A1ARG1ARG2 | |
| SCHEMBL24247663 | 0.81 | MAPT (0.33) | MAPTCACNA1BAPBA1SMN1; SMN2CYP3A4 | |
| Hydrochloric Acid SCHEMBL18951922 | 0.81 | KIF11 (0.36) | SMN1; SMN2ALOX5ALDH1A1ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120034364-A1 | USE OF PEPTIDES FOR IMPARTING KOKUMI | AJINOMOTO CO., INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034364-A1 | USE OF PEPTIDES FOR IMPARTING KOKUMI | GIPR, GABRA6, GABRB1 | MAPT 3274/4885CACNA1B 296/4885APBA1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.